Physician profile
Christopher J Webster
NPI 1437442613
$112,198.65
in general payments reported to CMS, 2019-2025
32 companies · $26K in 2025
The $26K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $692 · 2020: $548 · 2021: $874 · 2022: $31K · 2023: $3,926 · 2024: $49K · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $70K · Food and Beverage: $5,382 · Travel and Lodging: $3,319 · Consulting Fee: $243 · Education: $211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $69,827.50 |
| Food and Beverage | $5,381.81 |
| Travel and Lodging | $3,319.47 |
| Consulting Fee | $243.34 |
| Education | $211.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $34,562.09 | 2024-2025 | Jardiance, Zepbound, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $32,695.04 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24,909.78 | 2023-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $14,718.88 | 2019-2025 | Lokelma, Farxiga, Brilinta |
| Travere Therapeutics, INC. | $663.76 | 2021-2025 | |
| Vifor Pharma, INC. | $647.46 | 2019-2025 | Veltassa |
| Opko Pharmaceuticals, LLC | $570.23 | 2019-2025 | Rayaldee |
| Alexion Pharmaceuticals, INC. | $458.84 | 2019-2024 | Ultomiris |
| Amgen INC. | $391.08 | 2019-2025 | Tavneos, Krystexxa, Uplizna |
| Novo Nordisk INC | $377.44 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Aurinia Pharma U.S., INC. | $315.86 | 2021-2025 | Lupkynis |
| Calliditas Therapeutics US INC. | $306.36 | 2022-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $215.99 | 2023-2025 | |
| Glaxosmithkline, LLC. | $207.21 | 2020-2025 | Benlysta, Jesduvroq |
| Otsuka America Pharmaceutical, INC. | $186.41 | 2019-2025 | Jynarque, Voyxact |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $123.84 | 2019-2025 | Vafseo |
| Ardelyx, INC. | $119.35 | 2024-2025 | Ibsrela |
| Horizon Therapeutics Plc | $115.26 | 2022-2023 | Krystexxa |
| Fresenius USA Marketing, INC. | $110.60 | 2020-2024 | Velphoro |
| Amag Pharmaceuticals, INC. | $107.81 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $99.60 | 2020-2022 | |
| Mallinckrodt Enterprises LLC | $64.17 | 2019 | |
| Daiichi Sankyo INC. | $47.27 | 2019-2024 | Injectafer |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $34.78 | 2023 | |
| Apellis Pharmaceuticals, INC. | $34.69 | 2025 | Empaveli |
| Scpharmaceuticals INC. | $21.76 | 2025 | |
| Kyowa Kirin, INC. | $19.03 | 2025 | |
| Alnylam Pharmaceuticals INC. | $17.80 | 2025 | Oxlumo |
| Takeda Pharmaceuticals U.S.A., INC. | $15.22 | 2023 | Gattex |
| Ani Pharmaceuticals, INC. | $14.70 | 2025 | Purified Cortrophin Gel |
| Recor Medical INC | $14.08 | 2024 | Paradise Renal Denervation System |
| Ultragenyx Pharmaceutical INC. | $12.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Webster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.